Instruction for use: Prazosin (Prazosini)

Trade name of the drug – Prazosin, Polpressin

The Latin name of the substance Prazosin

Prazosinum (genus. Prazosini)

Chemical rational name: 1- (4-Amino-6,7-dimethoxy-2-quinazolinyl) - 4- (2-furanylcarbonyl) piperazine (in the form of a hydrochloride)

Gross formula C19H21N5O4

Pharmacotherapeutic group: Alpha-blockers

Drugs affecting the metabolism of the prostate gland and correctors urodynamics

The nosological classification (ICD-10)

I10 Essential (primary) hypertension: hypertension; Arterial hypertension; Arterial hypertension crisis course; Essential Hypertension; Essential hypertension; Essential hypertension; Essential hypertension; Essential hypertension; Primary hypertension; Arterial hypertension, complications of diabetes; The sudden increase in blood pressure; Hypertensive disorders of blood circulation; hypertensive condition; hypertensive crises; arterial Hypertension; malignant Hypertension; Hypertonic disease; hypertensive crises; accelerated hypertension; malignant hypertension; The aggravation of hypertensive disease; Transient hypertension; Isolated systolic hypertension

I15 Secondary hypertension: Arterial hypertension, complications of diabetes; hypertension; The sudden increase in blood pressure; Hypertensive disorders of blood circulation; hypertensive condition; hypertensive crises; hypertension; arterial Hypertension; malignant Hypertension; hypertensive crises; accelerated hypertension; malignant hypertension; The aggravation of hypertensive disease; Transient hypertension; hypertension; Arterial hypertension; Arterial hypertension crisis course; renovascular hypertension; Hypertension symptomatic; Renal hypertension; Renovascular hypertension; renovascular hypertension; Symptomatic hypertension

I50.9 Heart failure, unspecified: Diastolic stiffness; Diastolic heart failure; Cardiovascular failure; Heart failure with diastolic dysfunction; Cardiovascular failure

N40 Hyperplasia of prostate: Prostate adenoma; BPH; Prostatauxe; prostate Hypertrophy; Dysuric disorders caused by benign prostatic hyperplasia; Dizuricheskie disorder with benign prostatic hyperplasia; Dysuria with prostate cancer; Benign prostatic giperpalaziya; Benign prostatic hyperplasia; Benign prostatic hyperplasia stages 1 and 2; Benign prostatic hyperplasia I degree; Benign prostatic hyperplasia II degree; Benign prostatic hypertrophy; The disease of the prostate gland; Acute urinary retention related to benign prostatic hyperplasia; Benign prostatic hyperplasia stages 1 and 2 in combination with prostatitis; paradoxical ischuria

R39.1 Other difficulties with micturition: Frequent urination; urinary retention; Strangury; Obstructed flow of urine; Violation of urination; Violation of urination; Violation of bladder emptying; Violation of the outflow of urine; Frequent urination; Abnormalities of urination

CAS code 19216-56-9

Description of Prazosin

White or white with Valium a white crystalline powder. Very poorly soluble in 95% ethanol, practically insoluble in water.

Pharmacological Properties of Prazosin

Pharmachologic effect - Mode of action - hypotensive, vasodilatory, antidizuricescoe.

Selectively blocks postsynaptic alpha1-adrenergic receptors. Rapidly absorbed in the digestive tract, the rate of absorption is independent of food intake. Bioavailability - 50-85%. The proteins associated with blood of 97%. As a result, the degradation in the liver 4 formed metabolite, accounting for up to 25% of the pharmacological activity. T1 / 2 - 4.2 hours, renal insufficiency in the elderly and it increases. Excreted primarily in the bile.

It has a marked hypotensive effect without a significant increase in heart rate. Reduces round, expands capacitive and resistive vessels. Significantly reduces pressure in the pulmonary veins and right atrium, moderately - pulmonary vascular resistance. The first dose often causes a sharp drop in blood pressure (especially in orthostasis and in patients receiving diuretics). After the cancellation and subsequent appointment for a week this effect from the first dose is not observed. It reduces myocardial oxygen demand, increases stroke volume during exercise. Has minimal effect on fluid retention, no increase in body weight, does not change the filtration rate and renal blood flow, renal vascular resistance is reduced. Peak hypotensive effect observed after a single dose of 1-4 hours duration - up to 10 hours. It may develop as early (4-5 days) and late (to 12 months) tolerance, which requires increasing the dose. Favorably affect the lipid profile: reduced total cholesterol, triglycerides, VLDL and LDL; Tolerance does not alter carbohydrate metabolism or uric acid.

Indications for Prazosin

Hypertension, heart failure early stages of benign prostatic hyperplasia.

Contraindications for Prazosin

Hypersensitivity (including to other quinazolines), cardiac failure on the background of constrictive pericarditis, cardiac tamponade, defects with reduced left ventricular filling pressure, pregnancy, breast-feeding.

Restrictions to application

Hyponatremia.

Pregnancy and breast-feeding

Category effects on the fetus by FDA - C.

Side effect of Prazosin

The phenomenon of the first dose (sudden hypotension in orthostatic position, fainting, headache, weakness, palpitations), sleep disorders, weakness, fatigue, depression, nervousness, nausea, dry mouth, diarrhea, frequent urination, lower extremity edema, rash.

Interaction

It enhances the hypotensive effect of beta-blockers and diuretics.

Routes of administration

Inside.

Precautions for substance Prazosin

standing and lying should regularly monitor the blood pressure and heart rate in the state. The probability of hypotension is higher in patients receiving diuretics, sympatholytic beta-blockers.